Pimozide for schizophrenia or related psychoses

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Pimozide, an antipsychotic formulated in the 1960s, is used for schizophrenia and delusional disorder.
• It has been linked to cardiotoxicity and sudden death, necessitating ECG monitoring.
• This review evaluates pimozide's efficacy and safety against placebo and other antipsychotics.

Purpose of the Study:

• To review the effects of pimozide compared to placebo, no treatment, or other antipsychotic medications for schizophrenia.
• To examine pimozide's effects in individuals with delusional disorder.

Main Methods:

• Searched the Cochrane Schizophrenia Group's Register for relevant randomized clinical trials (RCTs).
• Independently assessed study quality, extracted data, and performed meta-analyses.
• Calculated relative risks and mean differences, assessing risk of bias and using GRADE for evidence quality.

Main Results:

• Pimozide demonstrated no significant difference in global state relapse compared to placebo or other antipsychotics.
• No significant differences were found in mental state improvements or first-rank symptoms.
• Extrapyramidal symptoms showed no significant group differences; however, data quality was often very low.
• Pimozide augmentation showed reduced relapse rates, but data for other outcomes were limited or skewed.

Conclusions:

• Pimozide exhibits comparable efficacy to commonly used antipsychotics like chlorpromazine for schizophrenia.
• Despite data limitations, pimozide's efficacy is consistent across various outcomes and timeframes.
• Current data is insufficient to support or refute the use of pimozide for delusional disorder.